Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › atezolizumab

atezolizumab

26 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of atezolizumab

83 trials tracked of atezolizumab: 21 in phase 3 or 4 and 17 with published results. The most-cited published study has 1701 citations.

83Trials tracked
21Phase 3 & 4
0Recruiting
17With published results
Phase distribution
Phase 4 1 Phase 3 20 Phase 2 54 Phase 1 7 Other / NA 1
  1. Phase 3 A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma Completed · 1,701 cited
  2. Phase 3 Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Completed · 798 cited
  3. Phase 3 A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma Completed · 662 cited
  4. Phase 3 A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed · 419 cited
  5. Phase 3 A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen Completed · 252 cited
  6. Phase 3 A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132) Completed · 188 cited
Show 44 more trials
  1. Phase 3 A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer Completed · 123 cited
  2. Phase 3 A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer Completed · 120 cited
  3. Phase 3 Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy Completed · 60 cited
  4. Phase 3 A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract Completed · 59 cited
  5. Phase 3 A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Completed · 54 cited
  6. Phase 4 A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Completed · 49 cited
  7. Phase 3 A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy Completed · 31 cited
  8. Phase 3 A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista Completed · 18 cited
  9. Phase 3 A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma Completed · 12 cited
  10. Phase 3 BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma Completed · 5 cited
  11. Phase 3 A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer Completed · 4 cited
  12. Phase 3 A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer Completed
  13. Phase 3 A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer Completed
  14. Phase 3 A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer Completed
  15. Phase 3 A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) Completed
  16. Phase 2 ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma Completed
  17. Phase 2 Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer Completed
  18. Phase 2 Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer Completed
  19. Phase 2 A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response Completed
  20. Phase 2 Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors Completed
  21. Phase 2 Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma Completed
  22. Phase 2 A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer) Completed
  23. Phase 2 A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases Completed
  24. Phase 2 A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer Completed
  25. Phase 2 A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer Completed
  26. Phase 2 Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer Completed
  27. Phase 2 Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma Completed
  28. Phase 2 A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer Completed
  29. Phase 2 A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy Completed
  30. Phase 2 A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML) Completed
  31. Phase 2 Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Completed
  32. Phase 2 A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Completed
  33. Phase 2 Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In Completed
  34. Phase 2 Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) Completed
  35. Phase 2 Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer Completed
  36. Phase 2 Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma Completed
  37. Phase 2 Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer Completed
  38. Phase 2 A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers Completed
  39. Phase 2 A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck Completed
  40. Phase 2 Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC Completed
  41. Phase 2 Atezolizumab Immunotherapy in Patients With Advanced NSCLC Completed
  42. Phase 2 Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis Completed
  43. Phase 2 Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis Completed
  44. Phase 2 A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma Completed

Showing the 50 most-cited and recently-updated of 83 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Case report and review of primary cervical melanoma shows inconsistent response to PD-1/PD-L1 inhibitors
Allergy & Immunology Sys. Review
Case report and review of primary cervical melanoma shows inconsistent response to PD-1/PD-L1 inhibitors Rare cervical melanoma cases show mixed results with immunotherapy and surgery
A case report of two patients with primary malignant melanoma of the cervix and a review of nine reported cases treated with PD-1/PD-L1 inhi…
Surgery alone fails for rare cervical melanoma, as 80% of patients progress on immunotherapy without chemotherapy or radiation.
Frontiers Apr 9, 2026
Atezolizumab with mFOLFOX6 Boosts 3-Year DFS by 10.1% in Stage III dMMR Colon Cancer
Oncology RCT
Atezolizumab with mFOLFOX6 Boosts 3-Year DFS by 10.1% in Stage III dMMR Colon Cancer Could a New Treatment Boost Survival for Stage III Colon Cancer Patients?
In a phase 3 trial, atezolizumab plus mFOLFOX6 improved 3-year disease-free survival to 86.3% vs. 76.2% with mFOLFOX6 alone (HR 0.50; 95% CI…
Adding atezolizumab to standard chemotherapy boosted 3-year disease-free survival to 86% in stage III colon cancer patients, up from 76% wit…
Mar 27, 2026